The FDA has granted full approval to Eli Lilly's Inluriyo (imlunestrant) combined with Verzenio (abemaciclib) for treating adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy. This approval follows the Phase 3 EMBER-3 trial, where the combination doubled median progression-free survival to 11.1 months compared to 5.5 months with Inluriyo alone. The all-oral regimen targets two key drivers of tumor growth with manageable side effects and no new monitoring requirements. This treatment offers a significant new option for patients with resistant ER+ breast cancer and is now available in the U.S.
Following the FDA approval of Eli Lilly's Inluriyo combined with Verzenio, Eli Lilly's stock (LLY) trades at USD 1,148.05 on Pluang as of Sep 19, 2026 01:04 WIB, showing a slight 0.35% decline in one day. The stock holds a market cap of $1.03 trillion and has a dividend yield of 0.6%, with typical investor hold time around 92 days. Current Pluang order activity leans more towards selling at 63%.
Eli Lilly's TOGETHER-PsA Phase 3b trial showed that combining Taltz (ixekizumab) and Zepbound (tirzepatide) nearly tripled the number of patients achieving at least 50% reduction in psoriatic arthritis (PsA) disease activity after one year compared t...
Hims & Hers reported a surprise Q3 loss and cut its full-year profit outlook, causing its stock to drop 18%. Despite 48.6% revenue growth, the company missed revenue estimates and faced margin pressure due to lower-margin weight-loss products and int...
Hims & Hers stock dropped 25.67% in a week following its deal with Eli Lilly to expand access to weight-loss drugs, despite Lilly's modest share gains. The decline reflects challenges from Hims' shift to branded GLP-1 drugs, including a drop in gross...
The FDA requires all makers of GLP-1 medications to add warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden and possibly permanent vision loss. This decision follows a review of c...
Eli Lilly's GLP-1 pill Foundayo showed significant improvement in obstructive sleep apnea in Phase 3 trials, with FDA submission planned by end of 2026. Sales jumped from $98 million in Q2 to $184 million in Q3, driving a 28% stock rise this year. Th...
